An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

NCT01340443 · clinicaltrials.gov ↗

COMPLETED

Status

314

Enrollment

INDUSTRY

Sponsor class

Conditions

Diffuse Large B-Cell Lymphoma

Sponsor

Hoffmann-La Roche